Jeito holds €200m first close for maiden fund

The fund's target amounts to €500m, which the VC is planning to raise by the end of 2020.

Jeito, founded by Rafaèle Tordjman, was launched in 2018. Tordjman worked for France-based Sofinnova Partners from 2001 to 2017. Prior to joining Sofinnova, she worked as a physician and researcher in hemato-oncology. 

Goodwin is advising the VC on the fundraise.

Jeito was not available for comment at the time of publication.

Investors
Institutional investors and high-net-worth individuals are currently invested in the fund. Belgian bank BNP Paribas Fortis has announced it is backing Jeito I, while other institutional backers including BPI France, Axa, CNP and Aviva are also invested in the vehicle, according to several French press reports.

Investments
The fund should back around 15 European startups related to drug development, and support the commercialisation of their products in the US.

Jeito I will provide tickets in the €5-30m range and up to €80m for certain startups, according to French publication Capital Finance.  

People
Jeito I – Rafaèle Tordjman (founder, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Funds
• France
• Venture
• Healthcare
• France
• Venture